From Citizendium
Jump to navigation Jump to search
This article is a stub and thus not approved.
Main Article
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
This editable Main Article is under development and subject to a disclaimer.

Rofecoxib is a cyclooxygenase 2 inhibitor drug used as an analgesic until it was voluntarily withdrawn from the market by Merck & Co in September, 2004 due to increased cardiovascular complications.[1] This was in part due to concerns[2] about suppression of negative results due to rofecoxib in the VIGOR randomized controlled trial[3].

The association was first reported in the original report of the VIGOR trial in 2000[3], and was also reported in a systematic review of published and unpublished studies in 2001[4].